Parameswaran Hari is Chief Development Officer at Obsidian Therapeutics. OpenAlex indexes 917 publications with 27,053 citations (h-index 79); ClinicalTrials.gov lists 6 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 5% of Hematology / Oncology profiles in the findmyKOL directory.
Data verified 14 Aug 2026
Overview
Updated 14 Oct 2026
Parameswaran Hari, MD, is Chief Development Officer at Obsidian Therapeutics. The public record shows 917 publications with 27,053 citations (h-index 79), centered on Multiple Myeloma Research and Treatments, Hematopoietic Stem Cell Transplantation, CAR-T cell therapy research. It also documents an investigator role on 6 registered clinical trials, industry payments reported by 16 companies, 2 NIH-funded awards (2017–2020).
- Most recent indexed publication: 2025 · Journal of clinical oncology
- Top research focus: Multiple Myeloma Research and Treatments
- 6 registered trials on ClinicalTrials.gov
- Open Payments reporting from 16 companies
Generated from the cited public record · current as of 14 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 20 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 354.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 14 Oct 2026
Listed as an investigator on 6 registered studies on ClinicalTrials.gov. The most recent:
- S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration
Sponsor: SWOG Cancer Research Network
- Tinostamustine Conditioning and Autologous Stem Cell
Sponsor: Mundipharma-EDO GmbH
- Assessment of Allogeneic Hematopoietic Cell Transplantation in Medicare Beneficiaries With Multiple Myeloma
Sponsor: Center for International Blood and Marrow Transplant Research
Industry payments
Updated 14 Oct 2026
16 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- PFIZER INC.Program year202518 payments$282,000openpaymentsdata.cms.gov ↗
- GlaxoSmithKline, LLC.Program year20254 payments$47,300openpaymentsdata.cms.gov ↗
- PFIZER INC.Program year202417 payments$414,438openpaymentsdata.cms.gov ↗
Medicare prescribing footprint (2021)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Dermatology
27.3%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor27.3%Acyclovir100%Part D≥32 patientsNervous system
22.3%Opioid Agonist17.8%Oxycodone Hcl51%Morphine Sulfate Er49%Part D<11 patientsGabapentinoids4.5%Gabapentin100%Part D<11 patientsSensory organs
19.4%Corticosteroid19.4%Dexamethasone100%Part D≥23 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 14 Oct 2026
2 NIH research awards on record, funded 2017–2020 per NIH RePORTER. The latest:
- A Phase I Clinical Trial Testing Feasibility of Hematopoietic Stem Cell Gene Therapy Using Platelet Factor VIII to Safely Improve Hemostasis for Severe Hemophilia A with Inhibitory Antibodies
Medical College of Wisconsin
FY2020$1,596,167R01HL142791 - Core Clinical Centers for the Blood and Marrow Transplant Clinical Trials Network
Medical College of Wisconsin
FY2020$184,800UG1HL138641 - A Phase I Clinical Trial Testing Feasibility of Hematopoietic Stem Cell Gene Therapy Using Platelet Factor VIII to Safely Improve Hemostasis for Severe Hemophilia A with Inhibitory Antibodies
Medical College of Wisconsin
FY2019$1,774,215R01HL142791
Congress activity
Updated 14 Oct 2026
151 congress contributions (2006–2025) across AACR, ASCO, ASH, ESMO per OpenAlex. The most recent:
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 14 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Phase I/II Study of Adaptive Manufactured Lentiviral Anti-CD20/Anti-CD19 Chimeric Antigen Receptor T Cells for Relapsed, Refractory Mantle Cell Lymphoma.
Journal of clinical oncology
Clinical Trial2025 - Randomized Phase III SIERRA Trial of (131)I-Apamistamab Before Allogeneic Hematopoietic Cell Transplantation Versus Conventional Care for Relapsed/Refractory AML.
Journal of clinical oncology
Clinical Trial2025 - Daratumumab-based quadruplet therapy for transplant-eligible newly diagnosed multiple myeloma with high cytogenetic risk.
Blood cancer journal
Clinical Trial2024
Most-cited works
by citation count (OpenAlex)Network
Updated 14 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 14 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/parameswaran-hari-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - ResearchGate
researchgate.net/profile/Parameswaran-Hari
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗
Mentions by others
where others cite or feature them- Instagram
instagram.com/p/DUbYEgKkpTI
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →instagram.com ↗ - Other
theorg.com/org/obsidian-therapeutics/org-chart/parameswaran-hari
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →theorg.com ↗ - Other
curetalks.com/improvements-in-myeloma-survival-with-dr-parameswaran-hari
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →curetalks.com ↗ - X / Twitter
x.com/mcw_oncology
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →x.com ↗ - YouTube
youtube.com/watch
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →youtube.com ↗ - LinkedIn
LinkedIn profile lists title as "Chief Medical Officer, Obsidian Therapeutics" (variant of the CDO title given in the company's official press release)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →linkedin.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 14 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →ascopost.com ↗
- MBBS
University of Kerala
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →obsidiantx.com ↗ - MS
Medical College of Wisconsin
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →obsidiantx.com ↗ - MRCP (Member of the Royal College of Physicians)
UK internal medicine/hematology training
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →ascopost.com ↗ - Board Certified
Internal Medicine (American Board of Medical Specialties)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →healthgrades.com ↗ - Board Certified
Medical Oncology (American Board of Medical Specialties)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →healthgrades.com ↗
Editorial & leadership roles
journal and society appointments- Chief Development Officer
Obsidian Therapeutics
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →obsidiantx.com ↗ - Secretary
American Society for Transplantation and Cellular Therapy (ASTCT)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ascopost.com ↗ - Formerly Chief of the Division of Hematology and Oncology
Medical College of Wisconsin
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →obsidiantx.com ↗ - Formerly Armand J. Quick/William F. Stapp Professor of Hematology
Medical College of Wisconsin
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →ascopost.com ↗ - Formerly Senior Vice President
Clinical Science, Iovance Biotherapeutics
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →obsidiantx.com ↗
Secondary affiliations
appointments beyond the home institution- Formerly Director
Adult Blood and Marrow Transplant Program, Medical College of Wisconsin
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →mcw.edu ↗ - Data coordination role
Center for International Blood & Marrow Transplant Research (CIBMTR) / BMT CTN
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →ascopost.com ↗
Media & interviews
press, podcasts and appearances- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →vjhemonc.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗
- The ASCO Post video
"Parameswaran Hari, MD, on Multiple Myeloma: Expert Commentary on Four Key Abstracts" (ASCO20 Virtual Scientific Program)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ascopost.com ↗ - provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →bloodcancerstoday.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
No other directory profiles share this institution yet.
Kenneth Anderson, MD
Dana-Farber Cancer Institute
Paul Richardson, MD
Dana-Farber Cancer Institute
S Rajkumar, MD
Mayo Clinic
Meletios Dimopoulos, MD
National and Kapodistrian University of Athens